<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367272">
  <stage>Registered</stage>
  <submitdate>16/10/2014</submitdate>
  <approvaldate>29/10/2014</approvaldate>
  <actrnumber>ACTRN12614001145695</actrnumber>
  <trial_identification>
    <studytitle>The Perioperative Administration of Dexamethasone and Glucose concentrations in diabetic and non-diabetic surgical patients</studytitle>
    <scientifictitle>In diabetic and non-diabetic surgical patients, does the administration of perioperative dexamethasone compared to placebo, increase blood glucose concentrations</scientifictitle>
    <utrn>U1111-1162-9647</utrn>
    <trialacronym>PADDAG</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus</healthcondition>
    <healthcondition>Surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Random allocation to either Placebo, Dexamethasone 4mg or 8mg IV at induction of anaesthesia, within EACH of two strata ( diabetic or non-diabetic )This will be determined according to their know diabetic status. The allocation will be by the use of a random number generator</interventions>
    <comparator>Placebo ( intravenous saline bolus )</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Peak postoperative blood glucose concentrations</outcome>
      <timepoint>Hourly intraoperatively, and up to 6 hourly postoperaively up to 24 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical site infection as determined by microbiological culture or the use of antibiotics </outcome>
      <timepoint>30 days postoperatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Postoperative nausea and vomiting as determined with a Verbal Response Scale</outcome>
      <timepoint>24 hours postoperatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Pain as determined with a Verbal Response Scale (VRS)</outcome>
      <timepoint>24 hours postoperatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Recovery (QOR) using the QOR-15 tool</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disability [WHODAS]</outcome>
      <timepoint>One year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chronic post-surgical pain using the mBPI and Neuropathic pain questionnaire</outcome>
      <timepoint>One year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Surgical Complications [Dindo-CLavien grade]</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of hospital stay</outcome>
      <timepoint>Until discharged postoperatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sepsis using the Surviving Sepsis Guidelines and CDC criteria</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Elective surgical patients
Skin incision required
Surgical duration greater than one hour
At least one night hospital stay postoperatively
General anaesthesia
ASA grade 1-4
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pure regional anaesthesia
Hypersensitivity to study drug
Poorly controlled Type 1 diabetes mellitus
Sickle cell anaemia
Thalassemia
Surgical procedure within the previous 3 months
Surgical procedure planned within 30 days of the index procedure
Infection within three months prior to procedure
Maxillofacial surgery 
Intraoperative requirement
Renal Impairment
Immunosuppressive therapy or state
Concurrent systemic glucocorticoid usage
Moderate or severe liver disease
Metastatic cancer
Opthalmic surgery
Endovascular procedures

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Stratification according to presence or absence of diabetes
Double blinded
</concealment>
    <sequence>Simple randomisation using a computer random-number generator
Sequentially numbered, opaque, sealed envelopes 

</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Superiority design
We will need to recruit 112 experimental subjects and 112 control subjects, in each stratum ( diabetic and non-diabetic) , to be able to reject the null hypothesis with a Type I error of 0.05 and power of 0.8.   Total cohort = 112 x 6 = 672. We will recruit 700 patients allowing for a dropout rate of 2.5%.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>10/12/2014</anticipatedstartdate>
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate>22/07/2016</anticipatedenddate>
    <actualenddate>6/06/2016</actualenddate>
    <samplesize>700</samplesize>
    <actualsamplesize>286</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>23/07/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>Fremantle Hospital and Health Service - Fremantle</hospital>
    <postcode>6000 - Perth</postcode>
    <postcode>6160 - Fremantle</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Perth Hospital</primarysponsorname>
    <primarysponsoraddress>Wellington Street
Perth City
Western Australia
WA 6000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Medical Research Foundation</fundingname>
      <fundingaddress>Royal Perth Hospital
Box X2213
GPO Perth 6847
Western Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The proposed PADDAG trial is a prospective, stratified-randomised controlled trial to determine whether the use of intraoperative dexamethasone, a widely used antiemetic in adult surgical patients, is associated with an increased blood glucose concentration, and whether this increase is greater in patients with diabetes than in those without. Secondary outcomes will include the risk of infection, and the interaction between dexamethasone administration, diabetic status, glycaemic control and infective complications.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Fremantle Hospital Ethics Committee</ethicname>
      <ethicaddress>Alma Street
Fremantle
6160
Western Australia</ethicaddress>
      <ethicapprovaldate>14/08/2014</ethicapprovaldate>
      <hrec>14/46</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Tomas Corcoran</name>
      <address>Department of Anaesthesia and Pain Medicine
Level 4, North Block
Royal Perth Hospital
Wellington Street
Perth
WA, 6000</address>
      <phone>+61892241038</phone>
      <fax />
      <email>tomas.corcoran@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Pauline Coutts</name>
      <address>Department of Anaesthesia and Pain Medicine
Level 4, North Block
Royal Perth Hospital
Wellington Street
Perth
WA, 6000</address>
      <phone>+61892241036</phone>
      <fax />
      <email>Pauline.coutts@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Tomas Corcoran</name>
      <address>Department of Anaesthesia and Pain Medicine
Level 4, North Block
Royal Perth Hospital
Wellington Street
Perth
WA, 6000</address>
      <phone>+61892241038</phone>
      <fax />
      <email>tomas.corcoran@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Tomas Corcoran</name>
      <address>Department of Anaesthesia and Pain Medicine
Level 4, North Block
Royal Perth Hospital
Wellington Street
Perth
WA, 6000</address>
      <phone>+61892241038</phone>
      <fax />
      <email>tomas.corcoran@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>